Detail akcie Sanara MedTech Rg online

Business Summary: Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Sanara Medtech Inc revenues increased 19% to $27.8M. Net income before extraordinary items totaled $398K vs. loss of $620K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and development decrease of 20% to $760K (expense), Total Amort of Intangibles-excl Goodwill decrease of 16% to $545K (expense).